Genelux Corp. (GNLX)
2.635
-0.02
(-0.94%)
USD |
NASDAQ |
Aug 31, 11:39
Genelux EPS Diluted (Quarterly) : -0.2107 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.2107 |
| March 31, 2026 | -0.2022 |
| December 31, 2025 | -0.2452 |
| September 30, 2025 | -0.2098 |
| June 30, 2025 | -0.1965 |
| March 31, 2025 | -0.2145 |
| December 31, 2024 | -0.2585 |
| September 30, 2024 | -0.1873 |
| June 30, 2024 | -0.2215 |
| March 31, 2024 | -0.2924 |
| December 31, 2023 | -0.2526 |
| September 30, 2023 | -0.2005 |
| Date | Value |
|---|---|
| June 30, 2023 | -0.2251 |
| March 31, 2023 | -0.4221 |
| December 31, 2022 | -0.1423 |
| September 30, 2022 | 0.2079 |
| June 30, 2022 | -0.1194 |
| March 31, 2022 | -0.161 |
| December 31, 2021 | -0.1584 |
| September 30, 2021 | -0.1247 |
| June 30, 2021 | -0.2835 |
| March 31, 2021 | -0.127 |
| March 31, 2020 | -0.1597 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Arcutis Biotherapeutics, Inc. | 0.1104 |
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
| Anika Therapeutics, Inc. | 0.2412 |
| Savara, Inc. | -0.1587 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -9.471M |
| Total Expenses (Quarterly) | 9.471M |
| Enterprise Value | 103.73M |
| Earnings Yield | -32.94% |
| Normalized Earnings Yield | -32.94 |